Loading clinical trials...

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer | Clinical Trials | Clareo Health

TERMINATEDNA

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

A Pilot Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Renal Cell Carcinoma

NCT02542202•University of Chicago

View on ClinicalTrials.gov

Summary

This pilot clinical trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with kidney cancer that has spread to other places in the body (metastatic) or has come back (recurrent). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)
•Patients must have between 1 to 5 new or recurrent lesions suspicious for metastatic RCC on diagnostic imaging
•* Each extracranial lesion must be =\< 6 cm and amenable to SBRT or surgical excision
•* Patients must have 3 or fewer brain metastases, of size =\< 4 cm
•* Brain metastases must be treated prior to enrollment in the study; the modality of treatment of brain metastases can include surgical resection, whole brain radiotherapy, stereotactic radiosurgery, or any combination of the above

Exclusion Criteria

•Patients must have had at least a computed tomography (CT) of the chest, abdomen, and pelvis within 4 weeks of registration in the trial; CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms
•Patients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 month
•Patients may not have had prior bevacizumab, based on case reports of tracheoesophageal fistula in patients treated with bevacizumab and radiotherapy
•Eastern Cooperative Oncology Group (ECOG) performance status =\<2
•Age 18 years or older
•Life expectancy of \>= 3 months
•Patients must have normal organ and marrow function within 30 days of registration, as defined below:
•* Absolute neutrophil count \>= 500/mcL
•* Hemoglobin \>= 8.0 g/dL
•* Platelets \>= 50,000/mcL
+18 more criteria

Locations (1)

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, United States

Key Dates

Start Date

May 1, 2015

Primary Completion Date

March 23, 2023

Completion Date

March 23, 2023

Last Updated

May 30, 2024

Enrollment

ACTUAL participants

Conditions

Metastatic Renal Cell CancerRecurrent Renal Cell CarcinomaStage IV Renal Cell Cancer

Interventions

Stereotactic Body Radiation Therapy

RADIATION

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

NCT06391099

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Cutaneous Melanoma+2 more

View study

RECRUITING

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642

Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial Carcinoma+25 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 30, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

Inclusion Criteria

Exclusion Criteria

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer